Rob L. H. Jansen

4.4k total citations · 1 hit paper
39 papers, 1.8k citations indexed

About

Rob L. H. Jansen is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Rob L. H. Jansen has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 12 papers in Surgery and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Rob L. H. Jansen's work include Cancer Diagnosis and Treatment (10 papers), Colorectal and Anal Carcinomas (7 papers) and Tumors and Oncological Cases (7 papers). Rob L. H. Jansen is often cited by papers focused on Cancer Diagnosis and Treatment (10 papers), Colorectal and Anal Carcinomas (7 papers) and Tumors and Oncological Cases (7 papers). Rob L. H. Jansen collaborates with scholars based in Netherlands, United Kingdom and United States. Rob L. H. Jansen's co-authors include Geerard L. Beets, Jeroen W. A. Leijtens, Guido Lammering, Ronald M. van Dam, Monique Maas, Sanne Engelen, Meindert N. Sosef, Jeroen Buijsen, Doenja M. J. Lambregts and Patty J. Nelemans and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Rob L. H. Jansen

39 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer

2011 717 citations Monique Maas, Geerard L. Beets et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Rob L. H. Jansen

Since Specialization

Citations

This map shows the geographic impact of Rob L. H. Jansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob L. H. Jansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob L. H. Jansen more than expected).

Fields of papers citing papers by Rob L. H. Jansen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob L. H. Jansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob L. H. Jansen. The network helps show where Rob L. H. Jansen may publish in the future.

Co-authorship network of co-authors of Rob L. H. Jansen

This figure shows the co-authorship network connecting the top 25 collaborators of Rob L. H. Jansen. A scholar is included among the top collaborators of Rob L. H. Jansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob L. H. Jansen. Rob L. H. Jansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risk factors for cancer of unknown primary: a literature review 2023 ·BMC Cancer ·(unknown), (unknown), (unknown), Rob L. H. Jansen, Irıs D. Nagtegaal, Piet A. van den Brandt, Leo J. Schouten	6
2	Vegetable and fruit consumption and cancer of unknown primary risk: results from the Netherlands cohort study on diet and cancer 2022 ·BMC Cancer ·(unknown), Piet A. van den Brandt, (unknown), Rob L. H. Jansen, Leo J. Schouten	3
3	Meat consumption and cancer of unknown primary (CUP) risk: results from The Netherlands cohort study on diet and cancer 2021 ·European Journal of Nutrition ·(unknown), Piet A. van den Brandt, (unknown), Rob L. H. Jansen, Leo J. Schouten	6
4	Anthropometry, physical activity and cancer of unknown primary (CUP) risk: Results from the Netherlands cohort study 2020 ·Cancer Epidemiology ·(unknown), Piet A. van den Brandt, (unknown), Rob L. H. Jansen, Leo J. Schouten	5
5	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors 2017 ·The Oncologist ·Maikel Verduin, Jaap Zindler, (unknown), Rob L. H. Jansen, Sander Croes, Lizza Hendriks, Daniëlle B. P. Eekers, Ann Hoeben	20
6	Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study 2017 ·Annals of Surgical Oncology ·Kees Bisschop, (unknown), Jannet C. Beukema, Rob L. H. Jansen, Hans Gelderblom, Koert P. de Jong, H.J.T. Rutten, Cornelis J.�H. van de Velde, Theo Wiggers, Klaas Havenga, Geke A.P. Hospers	40
7	Herpes Encephalitis: A Mortal Complication in a Patient Treated with Immunosuppressive Drugs because of Immune-Related Adverse Events after Ipilimumab Treatment 2017 ·Case Reports in Oncology ·(unknown), Caroline Loos, Monique Anten, Rob L. H. Jansen	3
8	Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing 2016 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·André B. P. Kuilenburg, Judith Meijer, (unknown), Doreen Dobritzsch, Rutger Meinsma, Maartje Los, (unknown), Lida Zoetekouw, Rob L. H. Jansen, Vincent O. Dezentjé, (unknown), Roel J.W. van Kampen, Jens Michael Hertz, Raoul C. M. Hennekam	36
9	A phase I–II study on the combination of rapamycin and short course radiotherapy in rectal cancer 2015 ·Radiotherapy and Oncology ·Jeroen Buijsen, Jørgen van den Bogaard, Barry Jutten, Eric H J Belgers, Meindert N. Sosef, Jeroen W. A. Leijtens, Geerard L. Beets, Rob L. H. Jansen, Robert G. Riedl, Ruud Clarijs, Guido Lammering, Philippe Lambin	22
10	Outcomes of extended versus limited indications for patients undergoing a liver resection for colorectal cancer liver metastases 2013 ·HPB ·Ronald M. van Dam, Toine M. Lodewick, Maartje A. J. van den Broek, Mechteld C. de Jong, J.W.M. Greve, Rob L. H. Jansen, Marc H.A. Bemelmans, Ulf P. Neumann, Steven W.M. Olde Damink, Cornelis H.C. Dejong	39
11	Hyaluronic Acid as a Marker of Hepatic Sinusoidal Obstruction Syndrome Secondary to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases 2013 ·Annals of Surgical Oncology ·Maartje A. J. van den Broek, Celien P.H. Vreuls, (unknown), Rob L. H. Jansen, Annemarie A. van Bijnen, Simon Dello, Marc H.A. Bemelmans, Cornelis H.C. Dejong, Ann Driessen, Steven W.M. Olde Damink	21
12	Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer 2013 ·Radiotherapy and Oncology ·Jeroen Buijsen, Guido Lammering, Rob L. H. Jansen, Geerard L. Beets, J. Wals, Meindert N. Sosef, Marien O. den Boer, Jeroen W. A. Leijtens, Robert G. Riedl, Jan Theys, Philippe Lambin	39
13	Wait-and-See Policy for Clinical Complete Responders After Chemoradiation for Rectal Cancer breakdown → 2011 ·Journal of Clinical Oncology ·Monique Maas, Geerard L. Beets, Doenja M. J. Lambregts, Guido Lammering, Patty J. Nelemans, Sanne Engelen, Ronald M. van Dam, Rob L. H. Jansen, Meindert N. Sosef, Jeroen W. A. Leijtens, Karel W. E. Hulsewé, Jeroen Buijsen	717
14	MRI After Chemoradiotherapy of Rectal Cancer: A Useful Tool to Select Patients for Local Excision 2010 ·Diseases of the Colon & Rectum ·Sanne Engelen, Geerard L. Beets, Max J. Lahaye, Guido Lammering, Rob L. H. Jansen, Ronald M. van Dam, Joop Konsten, Jeroen W. A. Leijtens, Cornelis J.�H. van de Velde	46
15	Primary monophasic mediastinal, cardiac and pericardial synovial sarcoma: a young man in distress 2007 ·Netherlands Heart Journal ·C. de Zwaan, Leen van Garsse, Rob L. H. Jansen, Robert Jan van Suylen	14
16	Clinical and immunohistochemical analysis of patients with unknown primary tumour. A search for prognostic factors in UPT. 2004 ·PubMed ·Agnès J. van de Wouw, Rob L. H. Jansen, Arjan W. Griffioen, H.F.P. Hillen	38
17	The unknown biology of the unknown primary tumour: a literature review 2003 ·Annals of Oncology ·Agnès J. van de Wouw, Rob L. H. Jansen, Ernst‐Jan M. Speel, H.F.P. Hillen	89
18	Clinical relevance of apoptotic markers in breast cancer not yet clear 2002 ·APOPTOSIS ·J.J. Jager, Rob L. H. Jansen, Jan Willem Arends	12
19	Phase II study on cisplatin and ifosfamide in recurrent high grade gliomas 1998 ·European Journal of Cancer ·Martin J. van den Bent, Jan H.M. Schellens, Ch.J. Vecht, Pauline Smit, O. J. L. Loosveld, Jun Ma, Cees Tijssen, Rob L. H. Jansen, Johan M. Kros, Jaap Verweij	9
20	Repetitive Weekly Cycles of 4-Day Continuous Infusion of Recombinant Interleukin-2: A Phase I Study 1992 ·Journal of Immunotherapy ·(unknown), Rob L. H. Jansen, P.H.M. de Mulder, D. Batchelor, Andrew Galazka, R. L. H. Bolhuis, G. Stoter	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact